DK3171866T3 - Behandling af androgen deprivationsterapi-inducerede hedeture og knogletab ved anvendelse af cis-clomiphen - Google Patents
Behandling af androgen deprivationsterapi-inducerede hedeture og knogletab ved anvendelse af cis-clomiphen Download PDFInfo
- Publication number
- DK3171866T3 DK3171866T3 DK15824708.0T DK15824708T DK3171866T3 DK 3171866 T3 DK3171866 T3 DK 3171866T3 DK 15824708 T DK15824708 T DK 15824708T DK 3171866 T3 DK3171866 T3 DK 3171866T3
- Authority
- DK
- Denmark
- Prior art keywords
- clomiphen
- trips
- cis
- treatment
- bone loss
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462028540P | 2014-07-24 | 2014-07-24 | |
| PCT/US2015/041761 WO2016014812A1 (en) | 2014-07-24 | 2015-07-23 | Treating androgen deprivation therapy induced hot flashes and bone loss using cis-clomiphene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3171866T3 true DK3171866T3 (da) | 2020-11-09 |
Family
ID=55163768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15824708.0T DK3171866T3 (da) | 2014-07-24 | 2015-07-23 | Behandling af androgen deprivationsterapi-inducerede hedeture og knogletab ved anvendelse af cis-clomiphen |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9913815B2 (da) |
| EP (2) | EP3171866B1 (da) |
| JP (1) | JP6743001B2 (da) |
| KR (2) | KR20230005415A (da) |
| CN (2) | CN111346076A (da) |
| AU (1) | AU2015292519B2 (da) |
| CY (1) | CY1123861T1 (da) |
| DK (1) | DK3171866T3 (da) |
| ES (1) | ES2828305T3 (da) |
| HR (1) | HRP20201726T1 (da) |
| HU (1) | HUE051442T2 (da) |
| IL (2) | IL249989B (da) |
| LT (1) | LT3171866T (da) |
| MX (1) | MX2017000886A (da) |
| PL (1) | PL3171866T3 (da) |
| PT (1) | PT3171866T (da) |
| RU (2) | RU2020120156A (da) |
| UA (1) | UA121971C2 (da) |
| WO (1) | WO2016014812A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017000886A (es) | 2014-07-24 | 2017-08-10 | Aspen Park Pharmaceuticals Inc | Tratamiento con cis-clomifeno de sofocos y perdida osea inducidos por privacion de androgeno terapeutica. |
| FR3082842A1 (fr) * | 2018-06-21 | 2019-12-27 | Veru Inc. | Polymorphe de cis-clomiphene (zuclomiphene) et procedes d'utilisation de celui-ci |
| CA3098552A1 (en) | 2019-11-14 | 2021-05-14 | Apotex Inc. | Processes for the preparation of zuclomiphene and intermediates thereof |
| CA3098725A1 (en) | 2019-11-14 | 2021-05-14 | Apotex Inc. | Zuclpomiphene salts and crystalline forms thereof |
| CA3105944A1 (en) | 2020-01-22 | 2021-07-22 | Apotex Inc. | Crystalline forms of zuclomiphene citrate |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT951631B (it) | 1971-03-18 | 1973-07-10 | Richardson Merrell Spa | Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi |
| US4729999A (en) * | 1984-10-12 | 1988-03-08 | Bcm Technologies | Antiestrogen therapy for symptoms of estrogen deficiency |
| US20040214898A1 (en) | 2001-11-29 | 2004-10-28 | Steiner Mitchell S. | Methods for treating hot flashes |
| US20040213841A1 (en) * | 2001-11-29 | 2004-10-28 | Steiner Mitchell S | Methods for treating hot flashes and gynecomastia |
| CA2468719C (en) * | 2001-11-29 | 2011-05-24 | Gtx Inc. | Prevention and treatment of androgen-deprivation induced osteoporosis |
| US6762524B2 (en) * | 2002-08-01 | 2004-07-13 | Albert Six | Magnetic drive system for a vehicle differential |
| ZA200706016B (en) * | 2004-12-21 | 2008-12-31 | Musc Found For Res Dev | Compositions and methods for promoting wound healing and tissue regeneration |
| US8158828B2 (en) * | 2005-11-28 | 2012-04-17 | Gtx, Inc. | Nuclear receptor binding agents |
| US8637706B2 (en) * | 2005-11-28 | 2014-01-28 | Gtx, Inc. | Nuclear receptor binding agents |
| US20090215733A1 (en) * | 2008-02-26 | 2009-08-27 | Michael Charles Scally | Therapy for the prophylaxis or treatment of adverse body composition changes and/or decreased muscle strength after androgen or gnrh analogue intake |
| MX2017000886A (es) * | 2014-07-24 | 2017-08-10 | Aspen Park Pharmaceuticals Inc | Tratamiento con cis-clomifeno de sofocos y perdida osea inducidos por privacion de androgeno terapeutica. |
-
2015
- 2015-07-23 MX MX2017000886A patent/MX2017000886A/es unknown
- 2015-07-23 HU HUE15824708A patent/HUE051442T2/hu unknown
- 2015-07-23 EP EP15824708.0A patent/EP3171866B1/en active Active
- 2015-07-23 RU RU2020120156A patent/RU2020120156A/ru unknown
- 2015-07-23 WO PCT/US2015/041761 patent/WO2016014812A1/en active Application Filing
- 2015-07-23 UA UAA201700302A patent/UA121971C2/uk unknown
- 2015-07-23 KR KR1020227044756A patent/KR20230005415A/ko not_active Application Discontinuation
- 2015-07-23 US US15/327,726 patent/US9913815B2/en active Active
- 2015-07-23 CN CN202010205589.4A patent/CN111346076A/zh active Pending
- 2015-07-23 JP JP2017525313A patent/JP6743001B2/ja active Active
- 2015-07-23 KR KR1020177005185A patent/KR20170040797A/ko not_active IP Right Cessation
- 2015-07-23 PT PT158247080T patent/PT3171866T/pt unknown
- 2015-07-23 AU AU2015292519A patent/AU2015292519B2/en active Active
- 2015-07-23 RU RU2017105837A patent/RU2725086C2/ru active
- 2015-07-23 CN CN201580040181.3A patent/CN107072969B/zh active Active
- 2015-07-23 ES ES15824708T patent/ES2828305T3/es active Active
- 2015-07-23 EP EP20190827.4A patent/EP3769756A1/en active Pending
- 2015-07-23 PL PL15824708T patent/PL3171866T3/pl unknown
- 2015-07-23 LT LTEP15824708.0T patent/LT3171866T/lt unknown
- 2015-07-23 DK DK15824708.0T patent/DK3171866T3/da active
-
2017
- 2017-01-09 IL IL249989A patent/IL249989B/en unknown
-
2018
- 2018-01-25 US US15/879,861 patent/US10463635B2/en active Active
-
2019
- 2019-09-24 US US16/580,198 patent/US10758500B2/en active Active
-
2020
- 2020-10-26 HR HRP20201726TT patent/HRP20201726T1/hr unknown
- 2020-11-02 CY CY20201101032T patent/CY1123861T1/el unknown
-
2022
- 2022-01-20 IL IL290004A patent/IL290004A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3129018T3 (da) | Behandling af NAFLD og NASH | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3227262T3 (da) | Sulfidalkyl og pyridyl-revers-sulfonamidforbindelser til hbv-behandling | |
| DK3224269T3 (da) | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser | |
| DK3259253T3 (da) | Sulfonylureaer og relaterede forbindelser og brug af samme | |
| DK3234133T3 (da) | Crispr-baserede sammensætninger og fremgangsmåder til anvendelse | |
| DK3212226T3 (da) | Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser | |
| DK3198018T3 (da) | Vektorvarianter af adenoassocieret virus til højeffektiv genomredigering og fremgangsmåder dertil | |
| DK3851537T3 (da) | Behandling af hyperbilirubinæmi | |
| DK3240785T3 (da) | Småmolekylede hæmmere af laktasedehydrogenase og fremgangsmåder til brug deraf | |
| DK3218320T3 (da) | Fremgangsmåde til varmebehandling af naturligt ler og/eller zeoliter | |
| DK3144001T3 (da) | Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf | |
| DK3151832T3 (da) | Fremgangsmåder til øgning af tonisk hæmning og behandling af sekundær søvnløshed | |
| DK3209696T3 (da) | Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom | |
| DK3151859T3 (da) | Virkningsfuld og effektiv kontrol af serumphosphat til optimal knogledannelse | |
| DK3137596T3 (da) | Sammensætninger og fremgangsmåder til modulation af komplement faktor b-ekspression | |
| DK3189074T3 (da) | Sammensætninger og metoder til behandling og forebyggelse af inflammation | |
| DK3200815T3 (da) | Fremgangsmåder og sammensætninger til behandling af cancer | |
| DK3331879T3 (da) | Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne | |
| DK3558280T3 (da) | Forebyggelse og behandling af migræne | |
| DK3265641T3 (da) | Stigørenhed og fremgangsmåde | |
| DK3261644T3 (da) | Sammensætninger og fremgangsmåder til behandling af nethindenedbrydning | |
| DK3019167T3 (da) | Behandling af forhøjede niveauer af eosinophiler og/eller basophiler | |
| DK3089971T3 (da) | Forbindelser og fremgangsmåder til anvendelse | |
| DK3142664T3 (da) | Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme |